연구동향 분석

Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Tr

이대호 이정신 Jie Wang Te-Chun Hsia 김종석 Mauro Orlando 2015년

논문상세정보
인용/피인용
' Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Tr' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • eastasian
  • erlotinib
  • nonsquamous non-small cell lung cancer
  • pemetrexed
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,299 0

0.0%

' Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Tr' 의 참고문헌

  • Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with nonsquamous non-small cell lung cancer
    Lee DH Eur J Cancer 49 : 3111 ~ 3121 [2013]
  • Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with nonsquamous non-small cell lung cancer
    Lee DH Eur J Cancer 49 3111-3121 [2013]
  • TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Herbst RS J Clin Oncol 23 5892-5899 [2005]
  • TRIBUTE : a phase III trial of erlotinib hydrochloride(OSI-774)combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Herbst RS J Clin Oncol 23 : 5892 ~ 5899 [2005]
  • Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Bezjak A J Clin Oncol 24 : 3831 ~ 3837 [2006]
  • Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Bezjak A J Clin Oncol 24 3831-3837 [2006]
  • Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer : a randomized, open-label study
    Sun Y Lung Cancer 79 : 143 ~ 150 [2013]
  • Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer : a randomized, open-label study
    Sun Y Lung Cancer 79 143-150 [2013]
  • Screening for epidermal growth factor receptor mutations in lung cancer
    Rosell R N Engl J Med 361 : 958 ~ 967 [2009]
  • Screening for epidermal growth factor receptor mutations in lung cancer
    Rosell R N Engl J Med 361 958-967 [2009]
  • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Hanna N J Clin Oncol 22 : 1589 ~ 1597 [2004]
  • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Hanna N J Clin Oncol 22 1589-1597 [2004]
  • Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    Brugger W J Clin Oncol 29 : 4113 ~ 4120 [2011]
  • Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    Brugger W J Clin Oncol 29 4113-4120 [2011]
  • Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer : the Tarceva Lung Cancer Investigation Trial
    Gatzemeier U J Clin Oncol 25 : 1545 ~ 1552 [2007]
  • Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer : the Tarceva Lung Cancer Investigation Trial
    Gatzemeier U J Clin Oncol 25 1545-1552 [2007]
  • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer
    Scagliotti GV J Clin Oncol 26 : 3543 ~ 3551 [2008]
  • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer
    Scagliotti GV J Clin Oncol 26 3543-3551 [2008]
  • Mutations of the epidermal growth factor receptor gene in lung cancer : biological and clinical implications
    Kosaka T Cancer Res 64 : 8919 ~ 8923 [2004]
  • Mutations of the epidermal growth factor receptor gene in lung cancer : biological and clinical implications
    Kosaka T Cancer Res 64 8919-8923 [2004]
  • Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment
    Kaneda H Cancer Manag Res 5 : 91 ~ 101 [2013]
  • Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment
    Kaneda H Cancer Manag Res 5 91-101 [2013]
  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer : a randomised, double-blind, phase 3study
    Ciuleanu T Lancet 374 : 1432 ~ 1440 [2009]
  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer : a randomised, double-blind, phase 3 study
    Ciuleanu T Lancet 374 1432-1440 [2009]
  • Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer(FASTACT-2) : a randomised, double-blind trial
    Wu YL Lancet Oncol 14 : 777 ~ 786 [2013]
  • Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer(FASTACT-2) : a randomised, double-blind trial
    Wu YL Lancet Oncol 14 777-786 [2013]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 : 947 ~ 957 [2009]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 947-957 [2009]
  • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : a phase III trial : INTACT 2
    Herbst RS J Clin Oncol 22 : 785 ~ 794 [2004]
  • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : a phase III trial : INTACT 2
    Herbst RS J Clin Oncol 22 785-794 [2004]
  • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer : a phase III trial--INTACT 1
    Giaccone G J Clin Oncol 22 : 777 ~ 784 [2004]
  • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer : a phase III trial--INTACT 1
    Giaccone G J Clin Oncol 22 777-784 [2004]
  • First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
    Han JY J Clin Oncol 30 : 1122 ~ 1128 [2012]
  • First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
    Han JY J Clin Oncol 30 1122-1128 [2012]
  • Erlotinib in previously treated non-small-cell lung cancer
    Shepherd FA N Engl J Med 353 : 123 ~ 132 [2005]
  • Erlotinib in previously treated non-small-cell lung cancer
    Shepherd FA N Engl J Med 353 123-132 [2005]
  • Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
    Ohe Y Clin Cancer Res 14 : 4206 ~ 4212 [2008]
  • Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
    Ohe Y Clin Cancer Res 14 4206-4212 [2008]
  • Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer : results of an exploratory subgroup analysis of a phase III trial
    Yang CH J Thorac Oncol 5 : 688 ~ 695 [2010]
  • Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer : results of an exploratory subgroup analysis of a phase III trial
    Yang CH J Thorac Oncol 5 688-695 [2010]
  • EGFR mutational status in a large series of Caucasian European NSCLC patients : data from daily practice
    Gahr S Br J Cancer 109 : 1821 ~ 1828 [2013]
  • EGFR mutational status in a large series of Caucasian European NSCLC patients : data from daily practice
    Gahr S Br J Cancer 109 1821-1828 [2013]
  • Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Shigematsu H J Natl Cancer Inst 97 : 339 ~ 346 [2005]
  • Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Shigematsu H J Natl Cancer Inst 97 339-346 [2005]
  • A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC
    Von Pawel J J Clin Oncol 29 (S) [2011]
  • A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC
    Von Pawel J J Clin Oncol 29 S - [2011]
  • A note on quantifying follow-up in studies of failure time
    Schemper M Control Clin Trials 17 : 343 ~ 346 [1996]
  • A note on quantifying follow-up in studies of failure time
    Schemper M Control Clin Trials 17 343-346 [1996]